Clinical trials: Injection Drug Use
- Condition Injection Drug Use
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
SARS-CoV-2 Infection
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
- Trial name
- NCT05687877
- Where
- 18 sites in Japan
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Special Drug Use Investigation of Ciproxan Injection in Pediatrics
The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.
- Trial name
- NCT02555059
- Testing
- Cipro (Ciprofloxacin, BAYQ3939)
- Where
- Japan
- Volunteers
- 48 people
- Sponsor
- Bayer
Bipolar Disorder I
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for prevention of recurrence/relapse of…
- Trial name
- NCT04812379
- Testing
- Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)
- Where
- Japan
- Volunteers
- 535 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
NUCALA® Special Drug Use Investigation (EGPA, Long-term)
This study is a drug use investigation program of NUCALA. The objective of this study is to collect and assess information on the safety and effectiveness of the long-term use of NUCALA SC injection in daily clinical practice in…
- Trial name
- NCT03557060
- Testing
- Nucala
- Where
- Japan
- Volunteers
- 4,115 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.
- Trial name
- NCT03209492
- Testing
- Leuprorelin acetate
- Where
- Japan
- Volunteers
- 333 people
- Sponsor
- Takeda
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
The purpose of this survey is to examine the effect on quality of life (QOL) improvement and convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit)…
- Trial name
- NCT02134977
- Testing
- Leuprorelin Acetate
- Volunteers
- 2,816 people
- Sponsor
- Takeda
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
Infertility
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection…
- Trial name
- NCT06545877
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Ferring Pharmaceuticals
Cancer
Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for intravenous use in clinical settings of the following diseases: 1. T-cell acute lymphocytic leukemia (T-ALL) 2.
- Trial name
- NCT01376115
- Testing
- Nelarabine
- Where
- Japan
- Volunteers
- 343 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
BENLYSTA® Special Drug Use Investigation
The objective of this study is to collect and assess the information about long-term safety and effectiveness of Benlysta for intravenous injection and Benlysta for subcutaneous injection (hereinafter referred to as "Benlysta")…
- Trial name
- NCT03370263
- Testing
- Benlysta
- Where
- Japan
- Volunteers
- 1,514 people
- Sponsor
- GlaxoSmithKline
Acute Lymphocytic Leukemia
BESPONSA Injection 1 mg Special Investigation
The purpose of this study is to learn about the safety and effectiveness of BESPONSA. BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia.
- Trial name
- NCT05923112
- Where
- Japan
- Volunteers
- 421 people
- Sponsor
- Pfizer
Neovascular Glaucoma
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.
- Trial name
- NCT04519619
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 480 people
- Sponsor
- Bayer
Lymphoma, T-Cell, Peripheral
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2.
- Trial name
- NCT03742921
- Testing
- Istodax
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Celgene
Familial Hypercholesterolaemia, Hypercholesterolaemia
Specified Drug-use Survey of Leqvio for s.c. Injection.
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice
- Trial name
- NCT06275724
- Testing
- inclisiran
- Where
- 107 sites in Japan
- Volunteers
- 585 people
- Sponsor
- Novartis Pharmaceuticals
Life Threatening Bleeding, Factor Xa Inhibitor
Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg.
- Trial name
- NCT05454787
- Where
- 54 sites in Japan
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Spinal and Bulbar Muscular Atrophy
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
The purpose of this survey is to evaluate the long-term safety and efficacy of leuprorelin acetate injection kit 11.25 mg in patients with spinal and bulbar muscular atrophy (SBMA) in the routine clinical setting.
- Trial name
- NCT03555578
- Testing
- Leuprorelin Acetate
- Where
- Japan
- Volunteers
- 1,905 people
- Sponsor
- Takeda
Breast Cancer
Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
The purpose of this survey is to examine the safety and efficacy of long-term use (96 weeks) of leuprorelin acetate SR (slow release) 11.25 milligram (mg) for injection (Leuplin SR 11.25 mg for Injection) in premenopausal breast…
- Trial name
- NCT02154139
- Testing
- Leuprorelin acetate
- Volunteers
- 651 people
- Sponsor
- Takeda
Short Bowel Syndrome
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome.
- Trial name
- NCT05023382
- Testing
- Teduglutide
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Takeda
Diabetic Macular Edema
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
This was a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.
- Trial name
- NCT05526729
- Testing
- Beovu
- Where
- 76 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals